Navigation Links
New 'knock-out' gene model provides molecular clues to breast cancer
Date:9/5/2007

New insights into the role of estrogen receptor in mammary gland development may help scientists better understand the molecular origin of breast cancer, according to new research from the University of Cincinnati (UC).

About a decade ago, U.S. scientists at the National Institutes of Health (NIH) developed a standard estrogen receptor (ER) gene knock-out mouse model to study the estrogen receptors role in human diseases.

Unfortunately, because these mice lacked mammary glands as a consequence of genetic manipulation, using this model to study the relationship between the estrogen receptor and breast cancer proved ineffective, explains Sohaib Khan, PhD, professor of cell and cancer biology at UC.

Knocking out the estrogen receptor gene for the entire genome, as the NIH scientists did, doesnt just affect the function of the receptor in all estrogen-responsive organs. It also creates an imbalance in the bodys circulating sex hormone levels, which could affect other physiological functions, Khan adds. An alternative model was clearly needed to study the intricacies of estrogen receptors involvement in this disease.

Estrogen receptor is a cellular protein that binds with the hormone estrogen and facilitates action in different parts of the body, including the mammary gland. Research has shown that about 70 percent of breast cancer patients have estrogen receptor-positive breast cancer, meaning their tumors will have some beneficial response to anti-estrogen drugs like tamoxifen (ta-MOX-ee-fen, marketed as Nolvodex).

After two years of work, Khan says his team has developed a knock-out mouse model that will allow scientists to study the role of estrogen receptor in specific organs (for example, mammary glands) without affecting estrogen-signaling throughout the rest of its body.

Khan used what is called a conditional knock-out technique to develop a new mouse model that retains estrogen receptor in all tissues except mammary tissue, allowing scientists to study the receptors role in breast development and breast cancer.

Using this model, Khans team found that knocking out the gene only in mammary tissue resulted in abnormalities that compromised milk production in the nursing female. This suggests that estrogen expression is essential for normal duct development during puberty, pregnancy and lactation.

Khan and his coworkers report the creation of this model and its potential implications in an early online edition of the Proceedings of the National Academy of Sciences on Sept. 4, 2007, followed by the print issue Sept. 11, 2007. The study directly refutes previous research, which suggests that estrogen receptor in epithelial cells was not essential to normal mammary gland development.

Mammary tissue is made up of two cell typesstromal cells, which give the tissue structure, and epithelial cells, which make up the lining of the mammary gland and become cancerous in the majority of breast cancers.

Unlike other organs in the body, the mammary glands develop after birth in response to increases in circulating hormones. This triggers growth of a network of branched ducts throughout the breast tissue that do not change again until a woman becomes pregnant.

Even though the relationship between the estrogen receptor and breast cancer is well established, we still know very little about the receptors mechanism of action, explains Khan, corresponding author of the study. Unless we study those mechanisms more closely, improved strategies for breast cancer treatments will not be possible.

Premenopausal women with breast cancer are currently given five years of tamoxifen, a drug that blocks the estrogen receptor action in cancer cells, to prevent recurrence. Studies have shown that the drug reduces recurrence in 40 percent of the women who take it, but Khan says many women eventually develop resistance to the drug.

Using this unique mouse model, UC researchers are currently collaborating with scientists at Dana Farber Cancer Institute/Harvard Medical School to understand the relationship between estrogen-signaling and oncogene-mediated breast cancer development. Future findings from these studies could help scientists better understand the molecular origin of breast cancer and develop new drugs to more effectively treat it.


'/>"/>

Contact: Amanda Harper
amanda.harper@uc.edu
513-558-4657
University of Cincinnati
Source:Eurekalert

Related medicine news :

1. Down syndrome simulated in animal model after successful chromosome transplantation
2. Novel computer model for breast cancer
3. MRI, To Detect Remodeling Of Heart and Help Preserve Function
4. Synthetic protein found to relieve arthritis symptoms in animal model
5. Researchers Develop Mouse Model Of Brain Tumor
6. New Model for understanding Tumor Metastasis
7. Mathematical Model Can Now Help Predict Asthma Risk
8. Model Kate Moss - Re-Birth After Humiliation
9. Heart transplanted infants better model for developing AIDS treatment
10. Mice model to study bacterial therapeutic pathway
11. Womens Self-Esteem Not Lowered By Seeing Ultra Thin Models
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern Californian, Dr. Omkar Marathe ... from the David Geffen School of Medicine at UCLA. He trained in Internal Medicine ... his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had the ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the benefits of moderation, whether ... latter, setting the bar too high can result in disappointment, perhaps even self-loathing. However, ... their goal. , Research from PsychTests.com reveals that behind the tendency ...
(Date:6/24/2016)... , ... June 24, 2016 , ... June 19, 2016 ... dangers associated with chronic pain and the benefits of holistic treatments, Serenity Recovery ... are suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) is a disorder ...
(Date:6/24/2016)... Fla. (PRWEB) , ... June 24, 2016 , ... Global ... Trend magazine’s 2016 Legal Elite. The attorneys chosen by their peers for this recognition ... Florida. , Seven Greenberg Traurig Shareholders received special honors as members of this year’s ...
(Date:6/24/2016)... ... 2016 , ... Topical BioMedics, Inc, makers of Topricin and MyPainAway Pain Relief Products, join The ... raise to $12 an hour by 2020 and then adjusting it yearly to increase at ... the minimum wage, assure the wage floor does not erode again, and make future increases ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... 27, 2016  VMS Rehab Systems, Inc. ( www.vmsrehabsystemsinc.com ... whatever measures required to build a strong and stable ... currently listed on the OTC Markets-pink current trading platform. ... CEO, "We are seeing an anomaly in market trading ... only by the Company, but shareholders and market players ...
(Date:6/24/2016)... , June 24, 2016  Consumers have ... and regulators/payers have placed more emphasis on patient ... patient support programs in the pharmaceutical industry have ... medications. Consequently, pharmaceutical companies are focusing on becoming ... are providing products and services that improve health. ...
(Date:6/24/2016)... , June 24, 2016  Global Blood ... biopharmaceutical company developing novel therapeutics for the treatment ... today announced the closing of its previously announced ... stock, at the public offering price of $18.75 ... offering were offered by GBT. GBT estimates net ...
Breaking Medicine Technology: